Optimizing the Design of Blood–Brain Barrier-Penetrating Polymer-Lipid-Hybrid Nanoparticles for Delivering Anticancer Drugs to Glioblastoma

2021 ◽  
Author(s):  
Taksim Ahmed ◽  
Fuh-Ching Franky Liu ◽  
Chungsheng He ◽  
Azhar Z. Abbasi ◽  
Ping Cai ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Brain Barrier ◽  
Hybrid Nanoparticles ◽  
Blood Brain

scholarly journals A Microfluidic Multisize Spheroid Array for Multiparametric Screening of Anticancer Drugs and Blood–Brain Barrier Transport Properties

2021 ◽  
pp. 2004856
Author(s):  
Christoph Eilenberger ◽  
Mario Rothbauer ◽  
Florian Selinger ◽  
Anna Gerhartl ◽  
Christian Jordan ◽  
...  
Keyword(s):  
Transport Properties ◽  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals Complete inhibition of ABCB1 and ABCG2 at the blood–brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib

2020 ◽  
pp. 0271678X2096550
Author(s):  
Nicolas Tournier ◽  
Sebastien Goutal ◽  
Severin Mairinger ◽  
Irene Hernández-Lozano ◽  
Thomas Filip ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Rhesus Macaques ◽  
Embryonic Stem ◽  
Brain Barrier ◽  
Brain Delivery ◽  
Brain Distribution ◽  
Cancer Resistance ◽  
Egfr Inhibition ◽  
Blood Brain

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict at the blood–brain barrier (BBB) the brain distribution of the majority of currently known molecularly targeted anticancer drugs. To improve brain delivery of dual ABCB1/ABCG2 substrates, both ABCB1 and ABCG2 need to be inhibited simultaneously at the BBB. We examined the feasibility of simultaneous ABCB1/ABCG2 inhibition with i.v. co-infusion of erlotinib and tariquidar by studying brain distribution of the model ABCB1/ABCG2 substrate [11C]erlotinib in mice and rhesus macaques with PET. Tolerability of the erlotinib/tariquidar combination was assessed in human embryonic stem cell-derived cerebral organoids. In mice and macaques, baseline brain distribution of [11C]erlotinib was low (brain distribution volume, VT,brain < 0.3 mL/cm3). Co-infusion of erlotinib and tariquidar increased VT,brain in mice by 3.0-fold and in macaques by 3.4- to 5.0-fold, while infusion of erlotinib alone or tariquidar alone led to less pronounced VT,brain increases in both species. Treatment of cerebral organoids with erlotinib/tariquidar led to an induction of Caspase-3-dependent apoptosis. Co-infusion of erlotinib/tariquidar may potentially allow for complete ABCB1/ABCG2 inhibition at the BBB, while simultaneously achieving brain-targeted EGFR inhibition. Our protocol may be applicable to enhance brain delivery of molecularly targeted anticancer drugs for a more effective treatment of brain tumors.

Neisseria Meningitidis Opca Protein/MnO 2 Hybrid Nanoparticles for Overcoming Blood Brain Barrier to Treat Glioblastoma

2022 ◽  
pp. 2109213
Author(s):  
Cheng‐Yuan Dong ◽  
Qian‐Xiao Huang ◽  
Han Cheng ◽  
Di‐Wei Zheng ◽  
Sheng Hong ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Hybrid Nanoparticles ◽  
Blood Brain

scholarly journals Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma

2015 ◽  
Vol 18 (1) ◽  
pp. 27-36 ◽  
Author(s):  
Rajneet K. Oberoi ◽  
Karen E. Parrish ◽  
Terence T. Sio ◽  
Rajendar K. Mittapalli ◽  
William F. Elmquist ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio

2015 ◽  
Vol 32 (6) ◽  
pp. 2003-2014 ◽  
Author(s):  
Tianzhi Yang ◽  
Paige Martin ◽  
Brittany Fogarty ◽  
Alison Brown ◽  
Kayla Schurman ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Danio Rerio ◽  
Brain Cancer ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals CNS Targeted Nanoparticle Drug Delivery

2017 ◽  
pp. 229-245
Author(s):  
Dimple Sethi Chopra
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Brain Barrier ◽  
Polysorbate 80 ◽  
Coated Nanoparticles ◽  
Blood Brain ◽  
Nanoparticle Drug Delivery

The idea of formulating brain permeable nanoparticles stems from the need to treat various neurological disorders like Parkinson's disease, Alzheimer's disease, schizophrenia, depression and brain tumors. Neuropeptides, antibiotics, anticancer drugs and many CNS active drugs cannot cross blood brain barrier (BBB). Studies have revealed that when these drugs are loaded on to nanoparticles they not only cross BBB, but also exhibit decreased side effects. The drug can be dissolved, dispersed, encapsulated inside the nanoparticle or attached on to surface of nanoparticles. In 1995, dalargin was the first drug to be delivered across blood brain barrier (BBB) using polysorbate 80 coated nanoparticles. The size of nanoparticles is usually between 10-1000nm. For crossing BBB it should be less than 300 nm.

CNS Targeted Nanoparticle Drug Delivery

2017 ◽  
pp. 118-139
Author(s):  
Dimple Sethi Chopra
Keyword(s):  
Drug Delivery ◽  
Side Effects ◽  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Anticancer Drugs ◽  
Brain Barrier ◽  
Polysorbate 80 ◽  
Coated Nanoparticles ◽  
Blood Brain ◽  
Nanoparticle Drug Delivery

The idea of formulating brain permeable nanoparticles stems from the need to treat various neurological disorders like Parkinson's disease, Alzheimer's disease, schizophrenia, depression and brain tumors. Neuropeptides, antibiotics, anticancer drugs and many CNS active drugs cannot cross blood brain barrier (BBB). Studies have revealed that when these drugs are loaded on to nanoparticles they not only cross BBB, but also exhibit decreased side effects. The drug can be dissolved, dispersed, encapsulated inside the nanoparticle or attached on to surface of nanoparticles. In 1995, dalargin was the first drug to be delivered across blood brain barrier (BBB) using polysorbate 80 coated nanoparticles. The size of nanoparticles is usually between 10-1000nm. For crossing BBB it should be less than 300 nm.

Sign in / Sign up

Export Citation Format

Share Document